Completed OBSERVATIONAL NCT03558165

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay (LU-NGS-2)

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Cancer Panel

Sponsor: Princess Margaret Hospital, Canada

Interventions Oncomine Comprehensive Assay

Updated 9 times since 2018 Last updated: May 16, 2022 Started: Mar 1, 2018 Primary completion: Aug 20, 2020 Completion: Feb 18, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Lung Cancer Stage IV and is currently completed. Princess Margaret Hospital, Canada leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Feb 2023 — Jul 2024 [monthly]

Completed
Jun 2022 — Feb 2023 [monthly]

Completed

Status: Active Not Recruiting → Completed
May 2021 — Jun 2022 [monthly]

Active Not Recruiting

Status: Recruiting → Active Not Recruiting

▶ Show 4 earlier versions

Jan 2021 — May 2021 [monthly]

Recruiting
Sep 2020 — Jan 2021 [monthly]

Recruiting
Aug 2019 — Sep 2020 [monthly]

Recruiting
Jul 2018 — Aug 2019 [monthly]

Recruiting

First recorded

Mar 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Princess Margaret Hospital, Canada
The Princess Margaret Cancer Foundation
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada